C00-C97
Conditions
Interventions
Group 1: Immediate starter: during the first 3 months, all on-site visits without the need of diagnotic or therapeutic interventions (laboratories, punctions, chemotherapy, transfusions e.g.) are repl
Sponsors
Dekanat der Medizinischen Fakultät, Christian-Albrechts-Universität zu Kiel
Eligibility
Sex/Gender
All
Age
1 Years to 25 Years
Inclusion criteria
Inclusion criteria: Newly diagnosed malignant disease or malignant disease under Treatment OR condition after allogeneic hematopoietic stem cell Transplantation under drug-immunosuppressive therapy. AND age = 1 year to 25 years. AND therapy Duration from inclusion = 6 months. AND anticipated high-frequency contact phases ( = 2 doctor-patient contacts per week during therapy). AND internet access at home.
Exclusion criteria
Exclusion criteria: Inclusion criteria not available AND/OR poor language skills which do not allow for a video-/audio conference
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Statistical evidence of equivalence of telemedical support regard to severe complications compared to on-site visits. Therefore, the cumulative score of severe complications (NCI-CTCAE) is measured after 3 and 6 months. | — |
Secondary
| Measure | Time frame |
|---|---|
| Proof that the “time-to-antibiotic” is not prolonged by the telemedical intervention compared to on-site visits AND Proof that patients and their families experience improvements in their health care and health status using telemedicine. "PREMS" and "PROMS" are recorded. | — |
Countries
Germany
Contacts
Public ContactMartin Schrappe
Christian-Albrechts-Universität zu Kiel, Universitätsklinikum Schleswig-Holstein, Klinik für Kinder- und Jugendmedizin I, Pädiatrische Hämatologie und Onkologie,
Outcome results
None listed